LifeVantage Expands its Flagship Protandim® Product Line During its Elite Academy in Long Beach
SALT LAKE CITY,
| |||||
The new product, known as Protandim® NAD Synergizer™, is the company’s first such addition to the flagship line since the launch of Protandim® Nrf1 Synergizer™ in 2016.*
“Our Protandim® line of synergizers is really what distinguishes us from other health and wellness companies, and we’re proud to introduce this latest breakthrough in nutrigenomic science and the newest member of the Protandim® family to the U.S. market,” said LifeVantage CEO Darren Jensen. “We are blazing a new trail of products that don’t simply add or ‘supplement’, but, rather, that tell your body to ‘create’.”*
Similar to how its predecessors in the product line activate the Nrf1 and Nrf2 pathways to boost mitochondrial function and antioxidant production respectively, Protandim® NAD Synergizer™ has been specifically formulated to target the Nicotinamide Adenine Dinucleotide (NAD) molecule and NAD-dependent pathways to activate a class of proteins called sirtuins and, ultimately, increase sirtuin activity.*
Sirtuin activity has been linked to a host of health benefits. In addition to being responsible for cellular autophagy (cellular cleanup and renewal process), sirtuins improve mental focus and concentration, support positive mood and motivation, boost mental and physical energy, support the body’s healthy inflammation response, maintain cholesterol levels already in a healthy range, and support a healthy vascular system.*
Sirtuin activity naturally declines by as much as 60 percent as humans age. Research has long shown that sirtuin activity can be increased by as much as 94 percent through drastic caloric restriction. Protandim® NAD Synergizer™ has been shown to increase sirtuin activity by 100 percent in just 24 hours without restricting calories.*
“One of the distinctions between LifeVantage and our competitors is we’re flipping the switch on NAD dependent processes so that your body can produce and activate sirtuins,” said LifeVantage Sr. Vice President of Research & Development Dr. Brian Dixon. “The more we know what switches to flip and how to flip them, the greater the control we can have over maintaining our health. A number of variables can flip the switches. In our case, we flip them nutrigenomically — utilizing specific blends of nutrients to positively affect gene expression.”*
Protandim® NAD Synergizer™ was made available for purchase for the first time during the company’s
The entire Protandim family of products — Protandim® Nrf1 Synergizer™, Protandim® Nrf2 Synergizer™, and Protandim® NAD Synergizer™ — is also available for purchase in a new stack known as Protandim® Tri-Synergizer™.
To learn more about Protandim® NAD Synergizer™ and the entire Protandim line of products, visit www.lifevantage.com/products/protandim-tri.
*These statements have not been evaluated by the
About LifeVantage
Forward Looking Statements
This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believe", "hopes", "intends", "estimates", "expects", "projects", "plans", "anticipates", "look forward to", "goal", "may be", and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Examples of forward-looking statements include, but are not limited to, statements we make regarding our future growth, projected success in certain markets, distributor success, and shareholder value. Such forward-looking statements are not guarantees of performance and the Company's actual results could differ materially from those contained in such statements. These forward-looking statements are based on the Company's current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties include, among others, those discussed in greater detail in the Company's Annual Report on Form 10-K and the Company's Quarterly Report on Form 10-Q under the caption "Risk Factors," and in other documents filed by the Company from time to time with the
Investor Relations Contact:
Scott Van Winkle
Managing Director, ICR
(617) 956-6736
scott.vanwinkle@icrinc.com
Media Relations Contact:
Chris Taylor
Director of Communications, LifeVantage
(801) 432-9170
chtaylor@lifevantage.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ac6b1358-f642-4a88-b47e-6b2cc33b6413
Source: LifeVantage Corporation